PRESENTATIONS FROM OCULAR MELANOMA CONFERENCES

OM Diagnosis, Genetics, Treatment, and Research:

• KIMMTRAK Approved: Now What?  (Dr. Meredith McKean and Dr. Justin Moser; 50 minutes)

• Ocular Melanoma Mets Explained  (Dr. Meredith McKean, Dr. Justin Moser, and Dr. Maureen Sanger; 50 minutes)

• Standards of Care in Uveal Melanoma  (Dr. Peter Hovland, Dr. David Reichstein, and Dr. Amy Schefler; 55 minutes)

• What Is the INSIGHT Ocular Melanoma Patient Registry?  (Dr. Armin Afshar; 35 minutes)

• Your Eye After Treatment  (Dr. David Reichstein; 55 minutes)

Mental Health and Self-Advocacy:

Links to videotaped conference presentations on these two topics can be found on EyeMelanoma.org's Patient Empowerment webpage. 

Low Vision:  

Link to videotaped conference presentation on low-vision tools and techniques can be found on EyeMelanoma.org's Vision-Related Support webpage. 

All videotaped presentations from this conference

Video Recordings of Clinical Research Sessions: Part 1

• Primary Ocular Melanoma 101  (Dr. Carol Shield; 51:25 to 1:27:04)

• Post-Primary Treatment  (Dr. Sara Lally; 1:27:04 to 1:51:21)

• Surveillance and Adjuvant Therapy  (Dr. Rino Seedor; 1:51:21 to 2:10:00)

• Past, Present, and Future of Uveal Melanoma  (Dr. Takami Sato; 2:49:00 to 3:19:40)

Video Recordings of Clinical Research Sessions: Part 2

• Treatments for Metastatic Disease: Liver Directed Therapies  (Order of presenters: Dr. Rani Anne, Dr. Robert Adamo, and Dr. Carin Gonsalves; 0:00 to 1:08:07) 

• Treatments for Metastatic Disease: Immunotherapies  (Marlana Orloff; 1:08:07 to 1:34:52)

• Treatments for Metastatic Disease: Molecular Targeted Therapies  (Dr. Rino Seedor; 1:34:52 to 1:51:57)

• Basic Science Updates  (Dr. Andrew Aplin; 1:51:57 to 2:19:07)

• Closing Remarks  (Dr. Sara Selig; 2:19:07 to 2:25:00)

Video Recording 1:

• Current and Emerging Systemic Treatment Choices for Metastatic Uveal Melanoma  (Dr. Paul Nathan; 30 minutes)

Video Recording 2:

• Novel Treatments of Uveal Melanoma  (Prof. Jonas Nilsson; 20 minutes)

• Liver-Directed Therapies for Metastatic Uveal Melanoma  (Dr. David Eschelman; 20 minutes)

Video Recording 3:

• Australian National Uveal Melanoma Treatment Pathway  (Dr. John McKenzie; 20 minutes)

• Ocular Prostheses  (Ocularist Camille Loyer; 15 minutes)

Video Recording 4:

• A Global Survey on Ruthenium Eye Plaque Practice  (Dr. Lotte Fog; 15 minutes)

• Another Option in the Radiotherapy Toolkit: Gantry-Based Proton Therapy  (Dr. Amanda Deisher; 15 minutes)

• Proton Therapy for Uveal Melanoma  (Dr. Sachin Salvi; 20 minutes)

Video Recording 5:

• Pathology of Uveal Melanoma  (Prof. Penny McKelvie; 20 minutes)

• Transretinal Tumour Biopsy Techniques  (Prof. Heinrich Heimann; 15 minutes)

• Uveal Melanoma Biopsy at the Time of Plaque Brachytherapy  (Dr. Rod O'Day; 15 minutes)

Video Recording 6:

• Genetics and Genomics in Uveal Melanoma  (Dr. Peter Johansson; 15 minutes)

• Proteomics in Uveal Melanoma  (Prof. Sarah Coupland; 15 minutes)

• Liquid Biopsies in Uveal Melanoma  (Dr. Aaron Beasley; 15 minutes)

OM Diagnosis, Genetics, Treatment, and Research:

• Ocular Melanoma Advocacy  (Melanoma Research Foundation's Cassie Beisel; 50 minutes)

• Ocular Melanoma Clinical Trials  (Dr. Richard Carvajal, Dr. Marlana Orloff, Dr. Sapna Patel, and Dr. Sara Selig; 75 minutes)

• Upcoming Ocular Melanoma Treatments  (Dr. Richard Carvajal and Dr. Sara Selig; 35 minutes)

• VISION Registry Update  (Dr. Richard Carvajal and Dr. Sara Selig; 60 minutes)

All videotaped presentations from this conference

OM Diagnosis, Genetics, Treatment, and Research: 

• How My Patients Made Me a Better Ocular Oncologist  (Dr. Bertil Damato; 45 minutes)

• Keynote Presentation: What's New in Uveal Melanoma in 2021  (Dr. Prithvi Mruthyunjaya; 45 minutes)

• Making Drug Development Work For Uncommon Cancers  (Dr. Anthony Tolcher; 45 minutes)

• Navigating a Diagnosis of Metastatic Uveal Melanoma  (Dr. Adil Daud and Dr. Justin Moser; 50 minutes)

• Treatment of Advanced Uveal Melanoma  (Dr. Jose Lutzky; 45 minutes)

• Uveal Melanoma Genetics Explained  (Genetic counselor Jaime Jessen and Dr. Basil Williams; 50 minutes)

• What to Expect After Radiation Treatment for Uveal Melanoma: A Patient's Perspective  (Dr. Armin Afshar and Dr. Timothy Murray; 50 minutes)

• What's New in Uveal Melanoma — NCCN Guidelines' Prognostic Information and Standards of Care  (Dr. David Reichstein, Dr. Amy Schefler, and Dr. Andrew Stacey; 50 minutes) 

• Why Should I Join a Registry? About the INSIGHT Ocular Melanoma Patient Registry  (Dr. Armin Afshar and Dr. Bertil Damato; 45 minutes)

Mental Health and Self-Advocacy:

Links to videotaped conference presentations on these two topics can be found on EyeMelanoma.org's Patient Empowerment webpage. 

Low Vision:  

Links to videotaped conference presentations on low-vision tools and techniques can be found on EyeMelanoma.org's Vision-Related Support webpage. 

All videotaped presentations from this conference

All the meeting's ocular melanoma presentations can be viewed in the following two parts by anyone after free online registration. (Note: Select "not a healthcare professional" to eliminate pre-test process for continuing education credit.)

Part 1:

One-hour video — OM presentations begin at 11:50 mark in the following order:

• Potential Application of Liquid Biopsies for Uveal Melanoma  (Dr. Elin Gray; 6 minutes)

• Uveal Melanoma: Proteomic Biomarkers  (Dr. Vinit Mahajan; 5 minutes)

• Molecular-Guided Clinical Trial Design in Uveal Melanoma  (Dr. J. William Harbour; 7 minutes)

• Panel Discussion  (24 minutes)

View Part 1 as shown above

Part 2:

Two-hour video — In its first hour, OM presentations begin at 14:20 mark in the following order:

• Targeted Treatment of Uveal Melanoma with Viral-Like Drug Conjugates  (Dr. Ivana Kim; 6 minutes)

• Dose Reduction Strategies for Plaque Brachytherapy  (Dr. Miguel Materin; 5 minutes)

• Anti-VEGF vs. Intravitreal Steroids for Prevention of Vision Loss Due to Radiation Retinopathy  (Dr. Daniel Martin; 8 minutes)

• Panel Discussion  (26 minutes)

In its second hour, OM presentations begin at 1:07:10 mark in the following order:

• Drug Toxicities from Cancer Therapies  (Dr. Dan Gombos; 7 minutes)

• Machine Learning in Ocular Melanoma Detection  (Dr. Mandeep Sagoo; 8 minutes)

• AI-Based Histopathologic Tumor Analysis  (Dr. Zelia Correa; 6 minutes)

• Panel Discussion  (21 minutes)

• A Perspective on Unmet Needs in Uveal Melanoma  (Dr. Carol Shields; 10 minutes)

• Activating a Research Network to Tackle a Yet Uncured Disease: COOG2  (Dr. Thomas Aaberg, Jr.; 7 minutes)

• Panel Discussion  (25 minutes)

View Part 2 as shown above